Psilocybine
Phase 2Small molecule
Psilocybine is one of 12 small molecule programs targeting Hematopoietic and Lymphatic System Neoplasm. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in ISS
#DrugCompanyPhaseTrials
1Ginaton
PPeking University People's Hospital
Phase 3
Myrbetriq
AstellasPhase 1
Methylprednisolone Hemisuccinate
BBBB-Therapeutics B.V.
Phase 3
Psilocybine
UUniversity of Zurich
Phase 2
Acellular Adipose Tissue (AAT)
JJohns Hopkins University
Phase 2
Reboxetine
UUniversity of Zurich
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psilocybin1 trial
ISS1 trial
Hematopoietic and Lymphatic System Neoplasm1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Psilocybine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Zurich